IN2014MN01937A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01937A IN2014MN01937A IN1937MUN2014A IN2014MN01937A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A IN 1937MUN2014 A IN1937MUN2014 A IN 1937MUN2014A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A
- Authority
- IN
- India
- Prior art keywords
- subject
- metabolic syndrome
- diabetes mellitus
- risk
- level
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608350P | 2012-03-08 | 2012-03-08 | |
| EP12158680 | 2012-03-08 | ||
| EP12165062 | 2012-04-20 | ||
| PCT/EP2013/054801 WO2013132090A1 (en) | 2012-03-08 | 2013-03-08 | A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01937A true IN2014MN01937A (pl) | 2015-07-10 |
Family
ID=49115970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1937MUN2014 IN2014MN01937A (pl) | 2012-03-08 | 2013-03-08 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10520512B2 (pl) |
| EP (1) | EP2823316B1 (pl) |
| JP (1) | JP6262669B2 (pl) |
| CN (1) | CN103308670B (pl) |
| ES (1) | ES2684512T3 (pl) |
| IN (1) | IN2014MN01937A (pl) |
| RU (1) | RU2685713C2 (pl) |
| TR (1) | TR201811201T4 (pl) |
| WO (1) | WO2013132090A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103308689B (zh) * | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| EP3002589A1 (en) * | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| CA2977494A1 (en) * | 2015-02-27 | 2016-05-06 | Sphingotec Gmbh | A method for predicting the risk of obesity in a subject |
| US10473670B2 (en) | 2016-02-25 | 2019-11-12 | University Of Kentucky Research Foundation | Method of predicting obesity comprising measuring neurotensin |
| WO2022203533A1 (ru) * | 2021-03-25 | 2022-09-29 | Владимир Валерьевич ВОЛОБУЕВ | Способ оценки предрасположенности к различным формам сахарного диабета 2го типа |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8709871D0 (en) * | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5430047A (en) * | 1994-04-07 | 1995-07-04 | Warner-Lambert Company | Neurotensin antagonists |
| WO1995033474A1 (en) * | 1994-06-03 | 1995-12-14 | Tsumura & Co. | Medicinal composition |
| IL138214A0 (en) * | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6248527B1 (en) * | 1998-10-21 | 2001-06-19 | Millennium Pharmaceuticals, Inc. | Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| JP4399254B2 (ja) * | 2001-06-20 | 2010-01-13 | キッセイ薬品工業株式会社 | 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体 |
| MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
| DK2298278T3 (en) | 2002-06-07 | 2016-02-01 | Dyax Corp | Prevention and reduction of blood loss and inflammatory response |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| CA2580881A1 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag | Use of microproteins as tryptase inhibitors |
| DE102005003687A1 (de) * | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
| EP1872138A1 (en) * | 2005-04-11 | 2008-01-02 | AstraZeneca AB | A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes. |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
| CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| AU2009322043A1 (en) * | 2008-12-05 | 2011-07-07 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| ES2538002T3 (es) | 2009-01-07 | 2015-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama |
| CN102869678A (zh) | 2009-08-27 | 2013-01-09 | 科瓦根股份公司 | Il-17结合化合物及其医药用途 |
| JP2013509588A (ja) * | 2009-10-29 | 2013-03-14 | テシス バイオサイエンス， インコーポレイテッド | ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー |
| WO2011073214A2 (en) | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
| UA58612U (uk) * | 2010-06-04 | 2011-04-26 | Высшее Государственное Учебное Заведение «Украинская Медицинская Стоматологическая Академия» | Спосіб діагностики інсулінорезистентності у хворих на метаболічний синдром та цукровий діабет 2 типу |
| RS58839B1 (sr) | 2010-06-08 | 2019-07-31 | Pieris Pharmaceuticals Gmbh | Muteini lipokalina u suzama koji vezuju il-4 r alfa |
| CA2977494A1 (en) * | 2015-02-27 | 2016-05-06 | Sphingotec Gmbh | A method for predicting the risk of obesity in a subject |
-
2012
- 2012-10-08 CN CN201210509621.3A patent/CN103308670B/zh active Active
-
2013
- 2013-03-08 US US14/383,422 patent/US10520512B2/en active Active
- 2013-03-08 EP EP13708803.5A patent/EP2823316B1/en active Active
- 2013-03-08 IN IN1937MUN2014 patent/IN2014MN01937A/en unknown
- 2013-03-08 TR TR2018/11201T patent/TR201811201T4/tr unknown
- 2013-03-08 RU RU2014140427A patent/RU2685713C2/ru active
- 2013-03-08 WO PCT/EP2013/054801 patent/WO2013132090A1/en not_active Ceased
- 2013-03-08 JP JP2014560405A patent/JP6262669B2/ja active Active
- 2013-03-08 ES ES13708803.5T patent/ES2684512T3/es active Active
-
2019
- 2019-12-18 US US16/719,507 patent/US20200326350A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014140427A (ru) | 2016-04-27 |
| CN103308670A (zh) | 2013-09-18 |
| JP2015512048A (ja) | 2015-04-23 |
| ES2684512T3 (es) | 2018-10-03 |
| EP2823316A1 (en) | 2015-01-14 |
| CN103308670B (zh) | 2017-06-09 |
| US20200326350A1 (en) | 2020-10-15 |
| EP2823316B1 (en) | 2018-05-23 |
| RU2685713C2 (ru) | 2019-04-23 |
| TR201811201T4 (tr) | 2018-09-21 |
| US20150056203A1 (en) | 2015-02-26 |
| WO2013132090A1 (en) | 2013-09-12 |
| US10520512B2 (en) | 2019-12-31 |
| JP6262669B2 (ja) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013159872A8 (en) | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope | |
| HK1223795A1 (zh) | 拉喹莫德响应性的基因表达生物标志物 | |
| IN2014MN01937A (pl) | ||
| NZ630421A (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| NZ601590A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2013030578A3 (en) | Method for detecting nucleosomes | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| WO2010041046A3 (en) | Granin proteins as markers of heart disease | |
| MX2015012304A (es) | Metodo no invasivo para la medicion de metabolitos para la salud de la piel. | |
| WO2016044338A3 (en) | Methods and systems for diagnosing sleep disorders | |
| WO2014004889A3 (en) | Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm | |
| WO2014053466A3 (en) | System and method for assessing risk associated with a glucose state | |
| MX359328B (es) | Metodo para el diagnostico de enfermedad de niemann-pick. | |
| IN2014MN01940A (pl) | ||
| BR112015014232A2 (pt) | lesão renal aguda | |
| WO2011085057A3 (en) | Methods for detecting insulin autoantibody | |
| WO2014187884A3 (en) | Mirnas as non-invasive biomarkers for heart failure | |
| RU2010145662A (ru) | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью | |
| WO2015010042A3 (en) | Method of determination of risk of 2 hour blood glucose equal to or greater than 140 mg/di | |
| WO2015192854A3 (en) | Methods and tools for predicting steatohepatitis | |
| WO2013132089A3 (en) | A method for predicting the risk of getting cancer or diagnosing cancer in a female subject | |
| WO2016066862A3 (en) | A method for predicting the risk of obesity in a subject | |
| WO2013101276A3 (en) | Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway | |
| WO2014169011A3 (en) | Methods for treating immune diseases |